No Data
Buy Recommendation for Mereo Biopharma Group Plc Driven by Promising Clinical Programs and Strategic Positioning
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading
BTIG Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $6
LifeSci Capital Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $10
Needham Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Optimism in Mereo Biopharma: Strong Phase II Results and Strategic Advancements Fuel Buy Rating